William L. Heaton

BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia

Matthew S. Zabriskie, Christopher A. Eide, Srinivas K. Tantravahi et al. · Cancer Cell · 2014 · 366 citations · Full text

Medicine, Molecular Biology, Oncology +7

Calcilytic Compounds: Potent and Selective Ca2+Receptor Antagonists That Stimulate Secretion of Parathyroid Hormone

Edward F. Nemeth, Eric G. DelMar, William L. Heaton et al. · Journal of Pharmacology and Experimental Therapeutics · 2001 · 234 citations

Medicine, Endocrinology, Pharmacology +17

Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia

Anna M. Eiring, Brent D. G. Page, Ira L. Kraft et al. · Leukemia · 2014 · 133 citations · Full text

Medicine, Oncology, Pharmacology +12

SIRT5 Is a Druggable Metabolic Vulnerability in Acute Myeloid Leukemia

Dongqing Yan, Anca Franzini, Anthony D. Pomicter et al. · Blood Cancer Discovery · 2021 · 59 citations · Full text

Life Sciences, Cancer Biology, Oncology +17

Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion

William L. Heaton, Anna V. Senina, Anthony D. Pomicter et al. · Leukemia · 2018 · 51 citations · Full text

Life Sciences, Cell Biology, Immunology +16